Table 4.
Correlation of GBM patient and tumor characteristics with RPS27 mRNA expression.
| Patient and Tumor Characteristics | Correlation Coefficient r | p-Value | Statistical Test |
|---|---|---|---|
| Sex (female/male) | n.d. | 0.47 | ANOVA |
| Age | -0.07 | 0.66 | Non-parametric correlation |
| ECOG (median) | n.d. | 0.42 | ANOVA |
| Tumor volume | 0.01 | 0.93 | Non-parametric correlation |
| Tumor localization (left/right/both hemispheres) |
n.d. | 0.90 | ANOVA |
| Tumor localization (lobe: frontal/occipital/temporal/parietal/multifocal) |
n.d. | 0.27 | ANOVA |
| MGMT promoter methylation (unmethylated/methylated) |
n.d. | 0.43 | ANOVA |
| Ki67 staining | 0.33 | 0.04 | Non-parametric correlation |
| Surgical intervention | n.d. | 0.79 | ANOVA |
| (biopsy/incomplete resection/complete resection) Tumor growth pattern (multifocal/local relapse [primary tumor/relapse]/multifocal relapse [primary tumor/relapse]) |
n.d. | 0.84 | ANOVA |
| PFS | 0.04 | 0.83 | Non-parametric correlation |
| OS | -0.15 | 0.33 | Non-parametric correlation |
Correlation of RPS27 mRNA expression with selected patient and tumor characteristics were examined by non-parametric tests (Spearman’s Rho). Expression differences were examined by ANOVA (ddCT-values, posthoc test: Scheffe procedure or Dunnet T3). Significant results are shown in bold. ECOG = Eastern Cooperative Oncology Group scale; n.d. = not determined; MGMT = O6-methylguanine DNA-methyltransferase; PFS = progression-free survival; OS = overall survival.